KR
38
4
FLS
75
2
CPB
24
2
PAYX
51
4
ROK
47
-8
DGX
50
2
L
64
2
LEN
52
2
EQIX
62
2
STZ
57
2
M
25
5
KHC
11
2
AVGO
22
2
RRC
59
-4
OKE
81
3
CI
52
7
HAL
60
2
EW
39
2
LRCX
45
6
CTSH
54
-2
KR
38
4
FLS
75
2
CPB
24
2
PAYX
51
4
ROK
47
-8
DGX
50
2
L
64
2
LEN
52
2
EQIX
62
2
STZ
57
2
M
25
5
KHC
11
2
AVGO
22
2
RRC
59
-4
OKE
81
3
CI
52
7
HAL
60
2
EW
39
2
LRCX
45
6
CTSH
54
-2
Financhill
Back

Dianthus Therapeutics 10K Form

Sell
13

DNTH
Dianthus Therapeutics

Last Price:
22.35
Seasonality Move:
12.89%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive DNTH News And Ratings

See the #1 stock for the next 7 days that we like better than DNTH

DNTH Financial Statistics

Sales & Book Value

Annual Sales: $2.83M
Cash Flow: $-21.29M
Price / Cash Flow: 0
Annual Sales: $11.51
Price / Book: 1.96

Profitability

EPS (TTM): -2.50290
Net Income (TTM): $-67.09M
Gross Margin: --
Return on Equity: -23.69%
Return on Assets: -22.7%

Dianthus Therapeutics Earnings Forecast

Key Dianthus Therapeutics Financial Ratios

  • The Research & Development expenses have been 1,162.10% of Revenue.
  • The Net Earning history of DNTH is -1,541.22% of Total Revenues.
  • Per Share Earnings over the last 3 years have been positive in 0 years.

Dianthus Therapeutics Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: DNTH
Website: dianthustx.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 18.3
Quick Ratio: 18.07

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

DNTH Technical Analysis vs Fundamental Analysis

Sell
13
Dianthus Therapeutics (DNTH) is a Sell

Is Dianthus Therapeutics a Buy or a Sell?